baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC DIS.CERT. 06/25 22UA/ DE000HD1NMM8 /

20/06/2024 21:46:24	Chg.+0.310	Bid21:59:15	Ask21:59:15	Underlying	Strike price	Expiration date	Option type
67.420EUR	+0.46%	67.460 Bid Size: 500	67.470 Ask Size: 500	BIONTECH SE SPON. AD...	- -	27/06/2025	Call

GlobeNewswire 01/06 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 29/05 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 21/05 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 17/05 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

TeleTrader 06/05 BioNTech's Q1 revenue slumps 85% to €187.6M

GlobeNewswire 06/05 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 22/04 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 07/04 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

TeleTrader 20/03 BioNTech Q4 revenue plunges 65% to €1.48B

GlobeNewswire 20/03 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 20/03 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 11/03 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 07/03 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 06/03 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 08/02 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

GlobeNewswire 31/01 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...

GlobeNewswire 22/01 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...

TeleTrader 09/01 BioNTech sees $3.3B revenue for 2024, expanding into oncology

GlobeNewswire 09/01 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 21/12/2023 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...

GlobeNewswire 18/12/2023 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

GlobeNewswire 12/12/2023 BioNTech to Inaugurate First African Site on December 18, 2023

TeleTrader 06/11/2023 BioNTech Q3 revenue plummets 74% to €895M

GlobeNewswire 06/11/2023 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

GlobeNewswire 26/10/2023 Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...

UC DIS.CERT. 06/25 22UA/ DE000HD1NMM8 /

If you wish to receive reply to your feedback, please provide your email address.